Treating and Managing Patients with Drug Interactions

  HCVinHIV_DDI_Banner_v1.jpg

HCVinHIV_OnDemand.jpg

About the Program:

Program Overview:

As many as 7 million people worldwide are infected with both HIV and HCV. Because of the potential consequences of HCV infection, clinicians who care for HCV/HIV co-infected patients face many complex treatment issues, including when to start treatment, which treatments to use, how long to treat patients, and which treatments can be safely combined in this population. In addition, they must remain abreast of rapidly changing information on the treatment of HCV/HIV co-infected patients. This program, "Managing HCV/HIV Co-Infection: What Clinicians Need to Know," is a series of six internet symposia, each covering a specific topic in the treatment of HCV/HIV co-infected patients. Each one-hour symposium will feature an interview of an expert in the field of HCV treatment, who will review and discuss the most essential information and data HIV clinicians need to know.

The fourth internet symposium is being brought to you from Baltimore, Maryland and will cover, "Evaluating and Managing Potential Drug-Drug Interactions." This program will feature an interview with Charles Flexner, MD, from Johns Hopkins University by Mark Sulkowski, MD, from Johns Hopkins University. Dr. Flexner is a leading expert on pharmacokinetics and drug-drug interactions in patients with HCV/HIV Co-infection.

Back to Top

Target Audience:

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV and HCV infection.

Back to Top

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Appropriately screen patients for HCV to identify HCV/HIV co-infected patients in their practice
  • Develop effective strategies for treating HCV in HIV-positive patients
  • Apply the most recent information to the treatment of HCV/HIV co-infected patients to avoid drug-drug interactions, minimize adverse effects, and achieve successful outcomes
  • Discuss research on HCV drugs in development to apply this information to ongoing treatment decisions

Release Date: August 1, 2017

Expiration Date: August 1, 2018

Estimated time to complete the program: 1 hour, 15 minutes

Back to Top

Faculty:

Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Charles Flexner, MD
Professor of Medicine
Pharmacology and International Health
Associate Director, Graduate Training Program in Clinical Investigation
Deputy Director, Institute for Clinical and Translational Research
Johns Hopkins University School of Medicine
Baltimore, Maryland

Back to Top

Physician Continuing Medical Education:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Back to Top

European Continuous Medical Education Credit:

AMA PRA Category 1 Credits claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC®) granted by the UEMS. One AMA PRA Category 1 Credit is equivalent to one (1) hour of European EACCME Credit (ECMEC®), therefore up to 1.0 ECMEC® Credits are available.

Back to Top

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Charles Flexner, MD

  • Consulting Fees: Merck, ViiV Healthcare, Mylan
  • Contracted Research: Gilead (to JHU)

Mark Sulkowski, MD:

  • Contracted Research (to JHU): Abbvie, Gilead, Merck, Tobira
  • Consulting Fees: Abbvie, CoCrystal, Gilead, Janssen, Merck, Trek
  • Other: Gilead - DSMB Member
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Shultz, RN, MSN, CHCP have nothing to disclose.
Back to Top

Instructions for Participation and Credit

There are no fees for participating and receved CME credit for this activity.  During the period, August 1, 2017 through August 1, 2018, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 12288.  Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.  Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

Disclosure of Unlabled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.  

Back to Top

 

 

 

 

 

 

Back to Top 
 

PIM_small

VE logo 300px
 

  This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs

*Greenwich Mean Time



Prepare to print

Share this page:

Get link code to this page                     


Back to Top